United KingdomThe UK's National Health Service (NHS) could face significant financial strain due to a new UK-US trade deal, which requires the NHS to pay significantly more for new drugs. According to analysis published in the British Medical Journal, this increased spending could result in over 200,000 avoidable deaths by 2036 and exacerbate existing health inequalities. The deal, announced in December 2025, aims to provide patients with access to potentially life-saving medications but comes at the cost of diverting £44.7 billion from other essential NHS services by 2036. The government claims the initial financial impact will be limited to an extra £1 billion between 2025-26 and 2028-29, though no detailed projections beyond that period have been provided. Campaign groups such as Global Justice Now have criticized the lack of transparency surrounding the deal and warn that it risks undermining NHS services.
Bias read (Left): The article presents the trade deal as harmful to public health and emphasizes the potential loss of lives and worsening health inequalities, while criticizing the government for yielding to pressure from Trump and Big Pharma. The framing highlights negative outcomes for the NHS and criticizes the '
